You are here: Home » Companies » News
Business Standard

Alembic Pharma gets USFDA nod for Parkinson's disease treatment drugs

The company has received approval from the USFDA for its abbreviated new drug application Carbidopa and Levodopa extended-release tablets

Press Trust of India  |  New Delhi 

alembic pharma

Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Carbidopa and Levodopa extended-release tablets, used for treatment of Parkinson's disease.

The approved products are therapeutically equivalent to the reference listed drug Sinemet CR tablets of Merck Sharp & Dohme Corp.

The company has received approval from the (USFDA) for its abbreviated new drug application Carbidopa and Levodopa extended-release tablets in the strengths of 2.5 mg/100 mg and 50mg/200 mg, Alembic said in a BSE filing.

Quoting IQVIA sales data, the company said the two products had an estimated market size of $24 million for 12 months ended December 2018.

The company said it now has a total of 94 abbreviated new drug application (ANDA) approvals from the

Shares of Alembic Pharmaceuticals were trading at Rs 511.05 apiece, down 0.08 per cent, on the BSE.

First Published: Thu, June 06 2019. 12:20 IST
RECOMMENDED FOR YOU